Device type · CHP
Radioimmunoassay, Estradiol
Last checked: Nov 19, 2026Source: openFDAMethods & limitations
Product code
CHP
Clinical Chemistry
Device class
Class I
FDA decisions since 2015
0
510(k), De Novo and PMA
Adverse event reports
70
Received Nov 1, 2025 to Nov 19, 2026
How FDA classifies it
- Device type
- Radioimmunoassay, Estradiol
- Product code
- CHP
- Device class
- Class I
- Review panel
- Clinical Chemistry
- Regulation
- 21 CFR 862.1260
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for CHP
Latest FDA decisions
No 510(k), De Novo or PMA decisions for this product code since 2015.
Reports received
70
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
68
97% of reports
Injury reports
2
2.9% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 2 | 0 | 0 | 0 |
| Jan 24 | 8 | 0 | 0 | 0 |
| Feb 24 | 2 | 0 | 0 | 0 |
| Mar 24 | 9 | 0 | 0 | 0 |
| Apr 24 | 1 | 0 | 0 | 0 |
| May 24 | 7 | 0 | 0 | 0 |
| Jun 24 | 7 | 1 | 0 | 0 |
| Jul 24 | 1 | 0 | 0 | 0 |
| Aug 24 | 6 | 0 | 0 | 0 |
| Sep 24 | 1 | 1 | 0 | 0 |
| Oct 24 | 8 | 1 | 0 | 0 |
| Nov 24 | 1 | 0 | 0 | 0 |
| Dec 24 | 11 | 0 | 0 | 0 |
| Jan 25 | 5 | 0 | 0 | 0 |
| Feb 25 | 3 | 0 | 0 | 0 |
| Mar 25 | 10 | 0 | 0 | 0 |
| Apr 25 | 6 | 0 | 0 | 0 |
| May 25 | 12 | 0 | 0 | 0 |
| Jun 25 | 6 | 0 | 0 | 0 |
| Jul 25 | 9 | 0 | 0 | 0 |
| Aug 25 | 5 | 0 | 0 | 0 |
| Sep 25 | 5 | 0 | 0 | 0 |
| Oct 25 | 11 | 0 | 0 | 0 |
| Nov 25 | 6 | 0 | 0 | 0 |
| Dec 25 | 8 | 0 | 0 | 0 |
| Jan 26 | 4 | 0 | 0 | 0 |
| Feb 26 | 8 | 0 | 0 | 0 |
| Mar 26 | 5 | 0 | 0 | 0 |
| Apr 26 | 9 | 0 | 0 | 0 |
| May 26 | 6 | 1 | 0 | 0 |
| Jun 26 | 5 | 0 | 0 | 0 |
| Jul 26 | 3 | 0 | 0 | 0 |
| Aug 26 | 5 | 0 | 0 | 0 |
| Sep 26 | 4 | 0 | 0 | 0 |
| Oct 26 | 5 | 1 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
- High Test Results47
- Non Reproducible Results35
- Low Test Results28
- Incorrect Measurement11
- Incorrect, Inadequate or Imprecise Result or Readings6
- Chemical Problem2
- Output Problem2
- Failure to Calibrate1
- Insufficient Device Problem Information1
- Nonstandard Device1
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
- No Clinical Signs, Symptoms or Conditions69
- Insufficient Information2
- Unspecified Reproductive System or Breast Problem1
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- VIDAS CLINICAL VIDAS ESTRADIOL II 60 TESTS, CATALOG 30431-01Open, Classified
Z-0867-2023 · Started Nov 9, 2022 · Posted by FDA Jan 4, 2023
Reason given: As the temperature and time out of range was exceeded, product performances cannot be guaranteed
Cause as FDA categorized it: Storage
- Atellica IM Enhanced Estradiol (eE2) 100T - In vitro diagnostic use in the quantitative determination of estradiol SMN: 10995561 All lotsOpen, Classified
Siemens Healthcare Diagnostics, Inc.
Z-1020-2022 · Started Mar 3, 2022
Reason given: Falsely Elevated Results Observed with Plasma Specimens, could lead a clinician to misinterpret patient results
Cause as FDA categorized it: Under Investigation by firm
- Atellica IM Enhanced Estradiol (eE2) 500T - In vitro diagnostic use in the quantitative determination of estradiol SMN: 10995562 All lotsOpen, Classified
Siemens Healthcare Diagnostics, Inc.
Z-1021-2022 · Started Mar 3, 2022
Reason given: Falsely Elevated Results Observed with Plasma Specimens, could lead a clinician to misinterpret patient results
Cause as FDA categorized it: Under Investigation by firm
- Atellica IM Enhanced Estradiol (eE2) (REF) 500T - In vitro diagnostic use in the quantitative determination of estradiol SMN: 11206250 All lotsOpen, Classified
Siemens Healthcare Diagnostics, Inc.
Z-1022-2022 · Started Mar 3, 2022
Reason given: Falsely Elevated Results Observed with Plasma Specimens, could lead a clinician to misinterpret patient results
Cause as FDA categorized it: Under Investigation by firm
- ADVIA Centaur Enhanced Estradiol (eE2) 100T - In vitro diagnostic use in the quantitative determination of estradiol SMN: 10490889 All lotsOpen, Classified
Siemens Healthcare Diagnostics, Inc.
Z-1023-2022 · Started Mar 3, 2022
Reason given: Falsely Elevated Results Observed with Plasma Specimens, could lead a clinician to misinterpret patient results
Cause as FDA categorized it: Under Investigation by firm
- ADVIA Centaur Enhanced Estradiol (eE2) 500T - In vitro diagnostic use in the quantitative determination of estradiol SMN: 10491445 All lotsOpen, Classified
Siemens Healthcare Diagnostics, Inc.
Z-1024-2022 · Started Mar 3, 2022
Reason given: Falsely Elevated Results Observed with Plasma Specimens, could lead a clinician to misinterpret patient results
Cause as FDA categorized it: Under Investigation by firm
- ADVIA Centaur Enhanced Estradiol (eE2) (REF) 500T - In vitro diagnostic use in the quantitative detection of estradiol SMN: 10697757 All lotsOpen, Classified
Siemens Healthcare Diagnostics, Inc.
Z-1025-2022 · Started Mar 3, 2022
Reason given: Falsely Elevated Results Observed with Plasma Specimens, could lead a clinician to misinterpret patient results
Cause as FDA categorized it: Under Investigation by firm
- VIDAS Estradiol II, REF 30431-01Open, Classified
Z-0435-2022 · Started Sep 22, 2021
Reason given: bioMerieux has been receiving an increasing number of complaints linked to a VIDAS substrate error. It prevents the test from being run, therefore leads to potential delayed results as the user must run another test.
Cause as FDA categorized it: Nonconforming Material/Component
Showing the 8 newest of 31 recall records in FDA's data.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.